Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies

by Medical Finance
in Coronavirus
Study: Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization. Image Credit: Fit Ztudio/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Scientists from the Medical University of Vienna, Austria, have recently evaluated the cross-neutralizing potency of serum samples collected from coronavirus disease 2019 (COVID-19) vaccinated and unvaccinated individuals who have been infected with the omicron BA.1 or BA.2 variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The findings reveal that fully vaccinated individuals with omicron breakthrough infections can generate cross-reactive neutralizing antibodies against wild-type SARS-CoV-2, delta variant, and omicron BA.1 and BA.2 variants.

Study: Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization. Image Credit: Fit Ztudio/Shutterstock
Study: Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization. Image Credit: Fit Ztudio/Shutterstock

The study is currently available on the Research Square* preprint server while under consideration at a Nature Portfolio Journal.

Background

The most recently emerged omicron variant of SARS-CoV-2 exhibits a heavily mutated genome compared to other known variants of concern (VOCs). With high numbers of spike mutations, the variant is capable of evading host immunity induced by prior infection or vaccination. There are three distinct sub-lineages of the omicron variant, including BA.1, BA.2, and BA.3. All sub-lineages are characterized by a heavily mutated spike protein.

In individuals without pre-existing immunity, omicron BA.1 infections have been found to induce significantly lower level of neutralizing antibody response against SARS-CoV-2 variants that were circulating before the emergence of omicron. Currently, the BA.2 sub-lineage is gaining global dominance by rapidly replacing the BA.1 sub-lineage. This highlights the possibility of higher transmissibility and immune-evasion ability of the BA.2 sub-lineage than the BA.1 sub-lineage.

In the current study, the scientists have evaluated BA.1, BA.2, and delta-neutralizing ability of serum samples collected from individuals with primary or breakthrough BA.1 or BA.2 infection.

Study design

The scientists collected serum samples from three distinct groups of individuals. The first group included individuals with a history of wild-type SARS-CoV-2, BA.1, or BA.2 infection. The second group included fully vaccinated individuals (three doses of mRNA-based COVID-19 vaccine) with BA.1 or BA.2 breakthrough infection. The third group included individuals with or without prior infection who had received three doses of COVID-19 vaccine.

The neutralizing potency of collected serum samples was tested against wild-type SARS-CoV-2, delta variant, and omicron BA.1 and BA.2 variants.     

Important observations

The serum samples collected three weeks and three months after the third vaccine dose showed potent cross-neutralizing ability against omicron variants (BA.1 and BA.2). However, the neutralizing titer was significantly lower than that against the wild-type virus. The serum samples collected from individuals who had wild-type infection before receiving three vaccine doses also showed cross-neutralizing ability against omicron variants.

The serum samples obtained from wild-type or omicron (BA.1/BA.2)-infected individuals showed significantly lower neutralizing potency against tested variants. Specifically, samples collected three weeks and six months after wild-type infection showed significantly lower neutralizing titers against the omicron variants.

The samples collected from BA.1-infected individuals showed lower neutralizing potency against wild-type virus, delta variant, and BA.2 variant compared to that against the BA.1 variant. In contrast, samples collected after primary BA.2 infection failed to cross-neutralize other tested variants. However, samples collected from individuals with omicron breakthrough infections showed equivalent neutralizing potency against all tested variants (wild-type, delta, and omicron BA.1 and BA.2).

These findings indicate that infections with omicron variants in unvaccinated individuals, especially BA.2 infections, induce variant-specific neutralizing titers. In contrast, omicron breakthrough infections in vaccinated individuals with pre-existing immunity can induce cross-reactive neutralizing antibodies.

Study significance

The study highlights the significance of COVID-19 booster vaccination in inducing cross-neutralizing antibodies. Importantly, the study demonstrates that primary infections with omicron BA.1 and BA.2 induce variant-specific neutralizing antibodies. These two sub-lineages of the omicron variant have similar mutational landscape in the spike protein.

However, mutations present in the N-terminal domain (NTD) of these sub-lineages vary significantly. The antigenic difference observed between the BA.1 and BA.2 sub-lineages could be due to the variation in their NTDs, which contain potent neutralizing epitopes.

*Important notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19patients

by Medical Finance
May 24, 2022
0

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the...

Researchers analyze the role of self-deception in everyday life

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

by Medical Finance
May 24, 2022
0

In adults who had previously received a full regimen of a COVID-19 vaccine approved or authorized by the Food and...

Study: Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. Image Credit: Dmitry Demidovich/Shutterstock

SARS-CoV-2 Omicron variant rapidly takes over Delta viral strain in Norwegian households

by Medical Finance
May 24, 2022
0

In a recent pre-print study posted to the Research Square* server and currently under review at a Nature Portfolio journal,...

Study: Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. Image Credit: DesignPrax/ Shutterstock

Vaccination reduces risk of long-COVID

by Medical Finance
May 24, 2022
0

Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is estimated to affect about 2% of the population...

Study: Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. Image Credit: Letters-Shmetters/Shutterstock

High risk of COVID-19 breakthrough infections among vaccinated individuals with cancer

by Medical Finance
May 24, 2022
0

In a recent study published in the Journal of the American Medical Association (JAMA) Oncology, researchers examined the risk of...

Study: Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade. Image Credit: Kateryna Kon/Shutterstock

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

by Medical Finance
May 24, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers proposed and constructed receptor-blocking conserved non-neutralizing antibodies (ReconnAbs) effective towards...

Next Post
First patient-derived stem cell model developed for studying oculocutaneous albinism

New training scheme for convolutional neural networks automates cell segmentation and counting

Scientists identify a new switch for controlling motor proteins

Scientists discover how immune proteins defend plants against invading microorganisms

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: The Future of the COVID-19 Pandemic: How Good (or Bad) Can the SARS-CoV2 Spike Protein Get? Image Credit: Design_Cells / Shutterstock.com
    How will mutations change the SARS-CoV-2 spike protein in the future?
  • Study: Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19. Image Credit: Cristoph Burgstedt / Shutterstock.com
    The B and T cell responses to SARS-CoV-2
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply